A combination of a new drug—sacubitril, a neprilysin inhibitor—and the angiotensin receptor blocker valsartan has been approved for the treatment of heart failure, providing what experts are describing as a major advance in the care of heart failure patients. The approval, announced by the Food and Drug Administration on July 7, 2015, was based on the PARADIGM-HF study of 8400 patients with heart failure, which found that the combination reduced the risk of cardiovascular death and hospitalization for heart failure by 20% and reduced the risk for all-cause mortality by 16%. To read the full article, go to Cardiology News: http://www.ecardiologynews.com/specialty-focus/heart-failure/single-article-page/fda-approval-of-sacubitril-valsartan-combo-opens-new-chapter-for-heart-failure/87f0d168e2c536251e452d008dc2671c.html.